Evidence map›Paper›PMID 38997676›Full record

Trial reportBMC pulmonary medicine2024

Longitudinal lung function trajectories in response to azithromycin therapy for chronic lung disease in children with HIV infection: a secondary analysis of the BREATHE trial.

Tafadzwa Madanhire, Grace McHugh, Victoria Simms, Lucky Ngwira, Carmen Gonzalez-Martinez, Robina Semphere, Brewster Moyo, Claire Calderwood, Mark Nicol, Tsitsi Bandason and 3 more

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in BMC pulmonary medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02426112 (Bronchopulmonary Function in Response to Azithromycin Treatment for Chronic Lung Disease in HIV-infected Children), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02426112 phase3completednot on this map

Bronchopulmonary Function in Response to Azithromycin Treatment for Chronic Lung Disease in HIV-infected Children

TypeinterventionalSponsorLondon School of Hygiene and Tropical MedicineRan2016 to 2019Enrolled347ConditionsChronic Lung Disease, HIV InfectionArmsAzithromycin, Placebo
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Tafadzwa MadanhireThe Health Research Unit Zimbabwe, Biomedical Research & Training Institute, 10 Seagrave Road, Harare, Zimbabwe. Tafadzwa.Madanhire@lshtm.ac.uk.
Grace McHughThe Health Research Unit Zimbabwe, Biomedical Research & Training Institute, 10 Seagrave Road, Harare, Zimbabwe.
Victoria SimmsThe Health Research Unit Zimbabwe, Biomedical Research & Training Institute, 10 Seagrave Road, Harare, Zimbabwe.
Lucky NgwiraMalawi-Liverpool-Wellcome Trust Clinical Research Programme, Blantyre, Malawi.
Carmen Gonzalez-MartinezMalawi-Liverpool-Wellcome Trust Clinical Research Programme, Blantyre, Malawi.
Robina SemphereDepartment of Paediatrics and Child Health, University of Malawi College of Medicine, Blantyre, Malawi.
Brewster MoyoMalawi-Liverpool-Wellcome Trust Clinical Research Programme, Blantyre, Malawi.
Claire CalderwoodThe Health Research Unit Zimbabwe, Biomedical Research & Training Institute, 10 Seagrave Road, Harare, Zimbabwe.
Mark NicolDivision of Medical Microbiology, Department of Pathology, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
Tsitsi BandasonThe Health Research Unit Zimbabwe, Biomedical Research & Training Institute, 10 Seagrave Road, Harare, Zimbabwe.
Jon O OdlandFaculty of Health Sciences, UiT, The Arctic University of Norway, Tromsø, Norway.
Andrea M RehmanMRC International Statistics and Epidemiology Group, London School of Hygiene & Tropical Medicine, London, UK.
Rashida A FerrandThe Health Research Unit Zimbabwe, Biomedical Research & Training Institute, 10 Seagrave Road, Harare, Zimbabwe.

Funding

Medical Research Council MR/R010161/1Wellcome TrustWellcome Trust 206316_Z_17_Z
6 · The paper itself

Abstract

backgroundChronic lung disease (CLD) is common among children with HIV (CWH) including in those taking antiretroviral therapy (ART). Azithromycin has both antimicrobial and anti-inflammatory effects and has been effective in improving lung function in a variety of lung diseases. We investigated lung function trajectories among CWH with CLD on ART enrolled in a randomized controlled trial of adjuvant azithromycin. We also investigated factors that modified the effect of azithromycin on lung function.

methodsThe study used data from a double-blinded placebo-controlled trial conducted in Malawi and Zimbabwe of 48 weeks on azithromycin (BREATHE: ClinicalTrials.gov NCT02426112) among CWH aged 6 to 19 years taking ART for at least six months who had a forced expiratory volume in one second (FEV

resultsOverall, 347 adolescents (51% male, median age 15 years) were randomized to azithromycin or placebo. The median duration on ART was 6.2 (interquartile range: 3.8-8.6) years and 56.2% had an HIV viral load < 1000copies/ml at baseline. At baseline, the mean FEV

conclusionThere was no observed azithromycin effect on lung function z-scores at any time point suggesting no therapeutic effect on lung function.

trial registrationClinicalTrials.gov NCT02426112. First registered on 24/04/2015.

Indexed as

AzithromycinHIV InfectionsLung DiseasesAdolescentAnti-Bacterial AgentsChildChronic DiseaseDouble-Blind MethodFemaleForced Expiratory VolumeHumansLongitudinal StudiesLungMalawiMaleRespiratory Function TestsAnti-Bacterial AgentsAzithromycinAdolescentsAfricaAzithromycinChildrenChronic lung diseaseFEV1HIV

Identifiers

PMID38997676
PMCPMC11245797

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.